While most stocks in the cannabis sector have been trading on a downtrend for the past few months, Vitality Biopharma Inc (OTCMKTS:VBIO) is holding steady. VBIO stock is currently trading at $2.08 a share.
Vitality Biopharma is developing proprietary cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory disorders. Vitality's targeted prodrug technology enables delivery of cannabinoids to the site of disease while reducing or eliminating psychoactivity. The Company is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.On May 10, 2017, Vitality Biopharma Inc announced that it obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other "superbug" pathogens. Utilizing a list of the top drug-resistant pathogens from the United States Centers for Disease Control and Prevention (CDC), Vitality researchers screened for antimicrobial activity in their portfolio of compounds. Vitality Biopharma discovered new antimicrobial activities for cannabinoids, and as a result has filed for patent protection on the use of cannabinoids and cannabinoid prodrugs for the treatment of multiple pathogenic bacterial infections. Dr. Brandon Zipp, Director of R&D at Vitality. Robert Brooke stated:
"Our cannaboside prodrugs enable the targeted delivery of cannabinoids into the large intestine, where C.diff infections colonize, take over, and can cause severe damage. Our compounds are uniquely suited for performing this task, and it's now clear they may provide benefits to gut health through multiple mechanisms."
On Apr 20, 2017, Vitality Biopharma Inc released one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory bowel disease patient. The report is a case study titled, "Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy," and describes a 13-year-old boy with drug-resistant Crohn's disease and colitis who achieved clinical remission after oral administration of cannabinoids. The case study describes how the patient's disease could not be controlled by currently-approved pharmaceuticals, and how cannabinoid treatment led to near-immediate clinical improvement that was indicative of disease remission.Vitality Biopharma Inc filed an international patent application in March of 2017 that describes compounds discovered to be effective in a drug screening model of neural repair. The underlying patent rights are based on work performed by the Myelin Repair Foundation (MRF), a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis. Researchers discovered several investigational and FDA-approved drugs that are useful in effecting remyelination, a form of nervous system regeneration. The discoveries included a compound called Cannabidiol (CBD), that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. As a result, Vitality Biopharma has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders.Vitality Biopharma Inc announced on Mar 30, 2017, announced positive results for colon cancer indicating a new use for the Company's proprietary prodrug cannabinoid delivery platform. The Company found that cannabidiol (CBD) universally inhibited cell growth at concentrations similar to established chemotherapeutics. Vitality also found that its cannabidiol prodrug was not toxic to the human cells at the concentrations tested, demonstrating the relative safety of its prodrug delivery system. Robert Brooke, CEO of Vitality stated:
"This finding means our proprietary cannabosides could be quite useful for treatment or prevention of colorectal cancer, even with hard-to-treat cancers, and without the systemic toxicity of DNA-damaging chemotherapies."
On the financial front, the latest published quarterly financial reports for the period ending March 31, 2017, do indicate steady revenues, but not at a scale necessary for growth. The Company is operating at a Net Loss. On a brighter side, the Company has very little debt, and plenty of cash on hand to execute its plan. Current market capitalization stands at $46.31 million, on 22.27 million shares outstanding as of July 7, 2017.Vitality Biopharma Inc is making great strides on the research and development front. It's only a matter of time before a major breakthrough happens and takes the stock price higher. Be sure to check out our previous complete coverage of VBIO. We will be updating our subscribers as soon as we know more. For the latest updates on VBIO, sign up below.Image courtesy of FlickrDisclosure: We have no position in VBIO and have not been compensated for this article.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
